trans-4-Methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 3, 1998, Pages 243-248

  Shih, Neng Yang ^a   Aslanian, Robert ^a   Lupo Jr , Andrew T ^a   Orlando, Steve ^a   Piwinski, John J ^a   Green, Michael J ^a   Ganguly, Ashit K ^a   West, Robert ^a   Tozzi, Salvatore ^a   Kreutner, William ^a   Hey, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLHISTAMINE; HISTAMINE H3 RECEPTOR AGONIST; TRANS 4 METHYL 3 IMIDAZOYL PYRROLIDINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DRUG SYNTHESIS; ENANTIOMER; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

ANIMALS; GUINEA PIGS; ILEUM; IMIDAZOLES; MUSCLE CONTRACTION; PYRROLIDINES; RECEPTORS, HISTAMINE H3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

STAPHYLOCOCCUS PHAGE 3A;

EID: 17144459549     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00020-1     Document Type: Article

References (17)

1. 1. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Nature (London) 1983, 302, 832.
2. 2. Arrang, J.-M.; Garbarg, M.; Lancelot, J.-C.; Lecomte J.-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwanz, J.-C. Nature (London) 1987, 327, 117.
3. 3. Schwartz, J.-C.; Arrang, J.-M.; Garbarg, M.; Pollard, H. A. Agents Actions 1990, 30, 13.
4. 4. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Neuroscience 1985, 17, 553.
5. 5. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Neuroscience 1987, 23, 149.
6. 6. Schlicker, E., Betz, R., Gothert, M. Naunyn-Schmied. Arch. Pharmacol. 1988, 337, 588.
7. 7. Schlicker, E., Betz, R., Gothert, M. Naunyn-Schmied. Arch. Pharmacol. 1990, 324, 497.
8. 8. Clapham, J., Kilpatrick, G. J., Br. J. Pharmacol. 1992, 107, 919.
9. 9. Hey, J. A.; del Prado, M; Egan, R. W.; Kreutner, W.; Chapman, R. Eur. J. Pharmacol. 1992, 277, 421.
10. 10. Shih, N.-Y.; Lupo, Jr. A. T.; Aslanian, R.; Orlando, S.; Piwinski, J. J.; Green, M. J.; Ganguly A. K.; Clark, M. A.; Tozzi, S.; Kreutner, W.; Hey, J. A. J. Med. Chem. 1995, 38, 1593.
11. 3 receptor binding of each compound represents the mean of two independent experiments.
12. 1-mediated bronchospasm (in vivo); see ref 9.
13. 1-mediated bronchoconstrictor effect at doses ≥ 0.3 mg/kg, iv. Compound 8 produced significant bronchoconstrictor effects at a dose of 0.3 mg/kg, iv.
14. 13. Arrang, J.-M.; Schwartz, J.-C.; Schunack, W. Eur. J. Pharmacol. 1985, 117, 109.
15. 14. Resolutions (≥ 99% ee) were accomplished via chiral stationary phase HPLC of the di-t-BOC derivatives of (±)-3a. Absolute stereochemistry of the enantiomers of 3a were assigned based upon a single crystal X-ray analysis of the hydrocholide salt of (+)-3a.
16. 3-antagonists. The assay used is based on studies described previously: Trzeciakowski; see Trzeciakowski, J. P. J. Pharmacol. Exp. Ther. 1987, 243, 84.
17. 3-agonist activity was determined in vivo using a model previously described: Hey, J. A.; del Prado, M.; Egan, R. W.; Kreutner, W.; Chapman, R. W. Br. J. Pharmacol. 1992, 107, 347.